QuidelOrtho and BÜHLMANN Launch Innovative Turbo Assays for IBD Diagnosis on VITROS Systems

The Launch of Innovative Assays on QuidelOrtho's VITROS Systems



On July 14, 2025, QuidelOrtho Corporation and BÜHLMANN Laboratories AG announced a groundbreaking partnership that brings the fCAL® turbo and fPELA® turbo assays to QuidelOrtho's VITROS Systems. This exciting development aims to enhance and streamline the diagnosis of inflammatory bowel disease (IBD) and pancreatic insufficiency through the utilization of non-invasive testing.

Enhancements in Diagnostic Testing


The fCAL turbo assay is specifically designed to measure fecal calprotectin, an important biomarker in the assessment of IBD. Meanwhile, the fPELA turbo assay evaluates fecal pancreatic elastase, crucial for determining pancreatic function. Both assays utilize advanced particle-enhanced turbidimetric immunoassays, which provide rapid results – typically in under ten minutes – solidifying their role in modern diagnostic settings.

These turbo assays are now available for use on various VITROS Systems, including the XT 7600 and 5600 Integrated Systems, along with the VITROS 4600 Chemistry Systems. The use of these state-of-the-art assays is designed for laboratories seeking improved efficiency and accuracy in gastrointestinal health management.

Addressing Key Healthcare Trends


This strategic collaboration between QuidelOrtho and BÜHLMANN is tailored to align with significant healthcare trends. One major trend is the increasing demand for non-invasive diagnostic options. Patients and healthcare providers are actively pursuing cost-effective solutions that minimize the need for invasive procedures. By incorporating these assays into routine diagnostics, QuidelOrtho is responding to this demand, thus enhancing patient comfort and care efficacy.

The integration of fCAL and fPELA turbo assays represents a significant leap forward in personalized medicine and preventive care. These innovative tools facilitate a proactive approach towards managing gastrointestinal conditions, allowing for early intervention and more informed healthcare decisions, ultimately leading to better patient outcomes.

Key Features and Benefits


The fCAL and fPELA turbo assays boast several notable features:
  • - Rapid Turnaround Time: Results are available in less than 10 minutes, allowing for timely clinical decisions.
  • - Wide Reportable Ranges: These assays cover a broad spectrum of clinical scenarios, making them versatile tools in laboratory diagnostics.
  • - 90-Day On-Analyzer Stability: This feature ensures that tests can be performed without frequent recalibrations, making operations smoother for laboratories.
  • - Enhanced Compatibility: They work seamlessly with VITROS Automation Solutions for integrated testing workflows.
  • - Simplified Sample Preparation: Utilizing CALEX® Cap technology, sample extraction is made simpler and safer.

QuidelOrtho's Executive Vice President of Research and Development, Dr. Jonathan Siegrist commented, “The integration of BÜHLMANN's fCAL and fPELA turbo assays represents a significant advancement in IBD and pancreatic insufficiency diagnoses. This collaboration allows laboratories to provide fast results to aid in the diagnosis and management of IBD and pancreatic issues.”

Commitment to Healthcare Innovation


Christian Eberle, the CEO of BÜHLMANN Laboratories AG, expressed excitement about the collaboration, stating, “We are thrilled to expand the delivery of an efficient, automated solution for fecal biomarker testing. This partnership enhances stool extraction efficiency and streamlines the testing process.”

The collaboration stands as a testament to both companies' commitment to advancing healthcare through innovation. QuidelOrtho remains dedicated to enabling healthcare professionals with the tools required for effective and timely diagnostics, catering to the evolving landscape of patient care.

In summary, the release of the fCAL and fPELA turbo assays marks a pivotal moment in diagnostic testing, providing enhanced tools for the assessment of gastrointestinal health. This partnership signifies a forward step in the ongoing journey towards personalized, efficient, and patient-centered healthcare.

For more information, visit QuidelOrtho's website or connect with them on social media.

About QuidelOrtho Corporation


QuidelOrtho Corporation is a leading provider of in vitro diagnostics, specializing in solutions that transform data into actionable insights across various healthcare settings. The company is dedicated to improving health outcomes worldwide.

About BÜHLMANN Laboratories AG


BÜHLMANN Laboratories AG has been at the forefront of developing innovative in-vitro diagnostic assays since its inception nearly 50 years ago. They remain committed to excellence in research and product development in the field of diagnostic testing.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.